The policy based on pharmacoeconomic evaluation method should be the direction of policy improvement in the future. Based on the comparison between the price of patented drugs in China and the international level, it is found that the price level directly converted by exchange rate in China is still at a medium level, while the price converted by purchasing power parity factor is relatively high. It is found that the current domestic patent drug price policy is well implemented. Combined with the interview, it is found that some problems existing in the current patent drug price policy need the guidance of scientific methods. Conclusion and Suggestions At present, there is still room for improvement in the price policy of patented drugs in China. We should aim at improving the affordability of patented drugs in China, improve the negotiation price formation mechanism of patented drugs in China, and learn from international advanced methods, such as reference pricing method and pharmacoeconomic evaluation. It is also necessary to establish a monitoring system for the price and sales of patented drugs, which is conducive to promoting the development of the pharmaceutical industry and the formation of reasonable prices. It can also provide data for related research, enrich scientific research in the field of patented drug prices, and provide decision-making basis for related policies of patented drugs. In order to further improve the policy of negotiating and purchasing patented drugs, we should first formulate the process and guide of negotiating and purchasing patented drugs from the policy level, standardize the provision of drug evaluation materials in pharmaceutical enterprises, and ensure the formation of scientific and reasonable negotiation prices; Secondly, all government departments should also strengthen cooperation, and the medical insurance department should take the lead in ensuring the top-down implementation of the negotiation results and implement the linkage of quantity and price of drugs; Finally, it is necessary to strengthen the professional quality of professionals at all stages of drug negotiation and procurement and strengthen personnel training.